Sebastian Lewandowski

Team Leader at the Department of Clinical Neuroscience and Center for Molecular Medicine

2018 - ongoing

Postdoc
2008 - 2018 Ulf Eriksson group, Karolinska Institutet

PhD degree
2005 - Nencki Institute of Experimental Biology, Warsaw, Poland

MSc degree
1997 - University of Gdansk, Poland

Our team studies cellular mechanisms of cerebrovascular injury mechanisms in ALS neurodegeneration to find novel clinical biomarkers and therapeutic solutions.

Publication highlight:
Månberg A. et al. Nature Medicine, April 2021
"Altered perivascular fibroblast activity precedes ALS disease onset".

Nature Medicine News and Views, April 2021
"Is presymptomatic ALS perivascular?"

Karolinska Institute Press release.
"New type of cell contributes to increased understanding of ALS"

Our web resource for cell-specific gene expression in ALS:
https://alscellatlas.org/

We look at how blood vessel dysfunction and vascular remodelling lead to
increased severity of Amyotrophic Lateral Sclerosis (ALS) and FTD using
bioinformatics, in-vivo rodent models and clinical samples. We collaborate
with the leading neurology centres in Europe and US including UZ Leuven in
Belgium, Univ. Utrecht in Holland, Ulm Univ. in Germany and UCSD in San
Diego. Our results lead to novel off-label drug applications to therapy and
biomarkers in neurodegeneration including ALS, stroke and multiple sclerosis.

We offer Master student, PhD and Postdoc positions to highly motivated and 

PhD course director "The Vascular Brain"
2020 - ongoing

Lecturer and group discussion leader in the Biomedicine program
2008 - ongoing

MSc student supervision
2018 - ongoing